From 1 July 2026, important changes to the insurance arrangements for HESTA Super and HESTA Personal Super members became effective, including reduced insurance fees. We've also introduced non-lapsing binding beneficiary nominations.
In our latest investment update, we provide a performance and market recap for the 2025–2026 financial year. We also share how HESTA members are investing in Australian healthtech innovation.
As of 1 July 2026, employers are now required to pay employees’ superannuation guarantee (SG) entitlements at the same time as their salary and wages.
![]()
Our members trust us to look after their financial future. We use our data and insights to understand who they are, so we can better help them face the future with confidence. And as an industry fund, we partner closely with employers to meet the unique needs of your workforce.
![]()
More than one million Australians already trust us with their money. We have a history of delivering strong long-term returns# and were one of the first funds to earn SuperRatings' 20-year Platinum Performance rating.^
![]()
Partner with us for payroll and employer admin that’s simple, with a team that’s ready to support you from day one. Less time on super admin means more time focused on what you do best.
One online form and you'll be set up as an employer with HESTA.

Need to know what your obligations are? We'll walk you through it.

Explore our resources to help you support your employees, from their first day to their retirement.

HESTA received the Rainmaker ESG Leader Rating, earned by implementing environmental, social and governance principles to a high level, while also having a track record of strong investment performance.
*.
# Investments may go up or down. Past performance is not a reliable indicator of future performance.
^ Product ratings and awards are only one factor to be considered when making a decision. The rating is issued by SuperRatings Pty Ltd (SuperRatings) ABN: 95 100 192 283 a Corporate Authorised Representative (CAR No.1309956) of Lonsec Research Pty Ltd ABN 11 151 658 561, AFSL No. 421445. The rating is based on the six key assessment areas, of which performance is only one. Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and SuperRatings assumes no obligation to update. SuperRatings use proprietary criteria to determine awards and ratings and may receive a fee for the use of its ratings and awards. Visit superratings.com.au for ratings information. © 2026 SuperRatings. All rights reserved.
† The Zenith CW Pty Ltd ABN 20 639 121 403 AFSL 226872/AFS Rep No. 1280401 Chant West rating (assigned February 2025) is limited to General Advice only and has been prepared without considering your objectives or financial situation, including target markets where applicable. The rating is not a recommendation to purchase, sell or hold any product and is subject to change at any time without notice. You should seek independent advice and consider the PDS or offer document before making any investment decisions. Ratings have been assigned based on third party data. Liability is not accepted, whether direct or indirect, from use of the rating. Past performance is not an indication of future performance. Refer to www.chantwest.com.au for full ratings information and our FSG. Chant West Awards issued 21 May 2025 are solely statements of opinion and not a recommendation in relation to making any investment decisions. Awards are current for 12 months and subject to change at any time. Awards for previous years are for historical purposes only. Full details on Chant West Awards at https://www.chantwest.com.au/fund-awards/about-the-awards/